Advertisement

Topics

FDA Approves Novel Treatment for Hairy Cell Leukemia

15:00 EDT 14 Sep 2018 | Drugs.com

FRIDAY, Sept. 14, 2018 -- Lumoxiti (moxetumomab pasudotox-tdfk) injection has been approved to treat certain instances of relapsed or refractory hairy cell leukemia (HCL), the U.S. Food and Drug Administration said yesterday. Lumoxiti, a...

Original Article: FDA Approves Novel Treatment for Hairy Cell Leukemia

NEXT ARTICLE

More From BioPortfolio on "FDA Approves Novel Treatment for Hairy Cell Leukemia"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Leukemia
Leukemia is a type of cancer of the blood or bone marrow characterized by an abnormal increase of immature white blood cells called "blasts". Leukemia is a broad term covering a spectrum of diseases. In turn, it is part of the even broader grou...